# India Montelukast API Market

> India Montelukast API Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.8%
- **2024:** $ 50.5 Million
- **2025:** $ 55.95 Million
- **2035:** $ 156.07 Million
- **Key Players:** Merck & Co (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Cipla Ltd (IN), Aurobindo Pharma Ltd (IN), Hikma Pharmaceuticals PLC (GB), Zydus Cadila (IN), Sun Pharmaceutical Industries Ltd (IN)

**Report ID:** MRFR/HC/51336-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-montelukast-api-market-53097

---

## Market Summary

## **India Montelukast API Market Overview**

As per MRFR analysis, the India Montelukast API Market Size was estimated at 56.25 (USD Million) in 2023. The India Montelukast API Market Industry is expected to grow from 63.12 (USD Million) in 2024 to 210 (USD Million) by 2035. The India Montelukast API Market CAGR (growth rate) is expected to be around 11.547% during the forecast period (2025 - 2035).

### **Key India Montelukast API Market Trends Highlighted**

The India Montelukast API market is experiencing substantial trends driven by the increasing prevalence of allergic conditions and asthma among the population. As the prevalence of respiratory disorders continues to rise, there is a growing need for effective treatments. Montelukast is a preferred option due to its safety and efficacy. Critical market drivers are the government's health initiatives to enhance respiratory health, particularly through awareness campaigns.

The market potential for Montelukast APIs has significantly increased as a result of these initiatives, which have emphasized the necessity of accessible and affordable medication in the country. In addition, the trend toward more localized production is generating opportunities for Indian manufacturers, as they can capitalize on the increasing domestic demand and prepare for exports due to favorable regulatory frameworks.

The pharmaceutical sector is encouraged to innovate and improve its production capabilities through the Make in India initiative, which supports its development. This local focus not only reduces dependence on imports but also stimulates the overall economy by creating employment. The pharmaceutical industry has recently been motivated to investigate innovative drug delivery systems.

These systems and products enhance patient adherence in response to the increased interest in biologics and personalized medicine. The Montelukast API market has the potential to benefit from this trend, as companies adjust their products to satisfy the changing needs of patients. Furthermore, the market's scope is further expanded by the emergence of digital health solutions.

These solutions provide a means to improve patient education and streamline prescription processes. In general, these emerging trends and opportunities are fostering the expansion of the India Montelukast API market.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

## **India Montelukast API Market Drivers**

### **Rising Asthma and Allergic Diseases in India**

The increasing prevalence of asthma and allergic diseases in India is a significant driver for the India Montelukast Active Pharmaceutical Ingredient Market Industry. According to the Indian Asthma Care Group, approximately 15% of the Indian population suffers from asthma, with a particularly high incidence in urban areas due to pollution and lifestyle changes.

Organizations such as the Ministry of Health and Family Welfare are actively working to raise awareness and improve treatment options for asthma, which boosts the demand for drugs such as Montelukast. With the rise of asthma-related hospital admissions, estimated to be around 3.6 million annually, the need for effective treatments continues to grow, thereby leading to heightened consumption of the Montelukast API.

### **Government Initiatives and Increased Healthcare Investment**

The Indian government has been reinforcing its healthcare infrastructure, which indirectly benefits the India Montelukast Active Pharmaceutical Ingredient Market Industry. The National Health Policy 2017 aims to increase public health expenditure to 2.5% of GDP by 2025, which translates to enhanced access to healthcare for millions.

This initiative creates an environment that encourages research, development, and demand for pharmaceutical products such as Montelukast. With an estimated increase in healthcare investments of over 10% annually, the growth potential for the Montelukast API market appears promising. The National Pharmaceutical Pricing Authority also plays a vital role in regulating and promoting the fair pricing of essential drugs, further aiding market expansion.

### **Growing Awareness of Preventive Healthcare**

The shift towards preventive healthcare is increasingly prevalent among the Indian population, acting as a catalyst for the India Montelukast Active Pharmaceutical Ingredient Market Industry. A survey conducted by the Indian Market Research Bureau reveals that 65% of Indians now favor preventive medicine and regular health check-ups.

Organizations such as the Indian Medical Association are promoting awareness about the early adoption of long-term treatments for chronic conditions such as asthma. This growing awareness is leading to an increase in the prescription rates for Montelukast, therefore driving the overall market growth. The increase in preventive measures is projected to enhance the consumption of Montelukast by an estimated 20% in the coming years.

### **Evolving Pharmaceutical Manufacturing Capabilities**

The advancement in manufacturing technologies and capabilities in India is positively impacting the India Montelukast Active Pharmaceutical Ingredient Market. As per the Department of Pharmaceuticals, the Indian pharmaceutical industry has seen a shift towards modern manufacturing processes, resulting in enhanced efficiency and reduced costs. The implementation of Good Manufacturing Practices (GMP) is increasing the overall quality of Montelukast production, allowing for more competitive pricing.

This is particularly beneficial for domestic companies to expand their market share. The Hinloopen report indicates that pharmaceutical exports from India are expected to grow substantially, promoting the availability of Montelukast on a global scale and contributing to the domestic market's revenue.

## **India Montelukast API Market Segment Insights**

### **Montelukast API Market Application Insights**

The Application segment of the India Montelukast API Market has gained considerable traction due to the increasing prevalence of respiratory and allergic conditions, particularly in urban populations. With rising pollution levels and lifestyle changes, the demand for effective treatments is becoming more pronounced.

Asthma remains a significant area of focus as it affects millions of individuals across the country, particularly among children, highlighting the need for ongoing Research and Development efforts to enhance treatment options. Furthermore, Allergic Rhinitis is widely recognized as a common ailment, with a considerable portion of the population experiencing symptoms that affect daily life, thus driving market growth.

Bronchospasm represents another critical application as it is often associated with various respiratory diseases, necessitating the need for effective management solutions in healthcare. Additionally, Urticaria, characterized by an allergic reaction leading to hives, contributes to the market's importance as many seek relief from discomfort through pharmacological interventions.

The category of Others encompasses a variety of allergic and respiratory conditions that further underpin the market’s diversity. Each of these applications not only reflects a significant portion of the India Montelukast API Market but also reveals a growing public awareness of health and well-being, indicating a robust growth trajectory.

Factors such as increased healthcare spending, a surge in awareness programs about allergies and asthma, and the ongoing efforts by the government and health organizations to improve healthcare accessibility are expected to continue driving the demand within this segment, presenting opportunities for innovation and market expansions to address unfulfilled needs among patients.

Overall, the Application segment can be seen as a vital contributor to the India Montelukast API Market, aligning well with broader healthcare trends and population health dynamics.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

## **India Montelukast API Market Key Players and Competitive Insights**

The India Montelukast API Market is characterized by a dynamic landscape driven by the increasing demand for asthmatic medications and allergy treatments. As a key player in the pharmaceutical domain, Montelukast serves as a leukotriene receptor antagonist that is widely prescribed for managing asthma and allergic rhinitis.

The market has seen a surge in both domestic and international players due to favorable regulatory policies, along with a growing awareness of respiratory disorders among the Indian population. Competitive insights reveal a blend of established pharma companies and emerging entities working towards innovation and cost-effective production strategies.

This competitive environment is further enhanced by partnerships, collaborations, and advancements in technology, which streamline manufacturing processes and enhance product quality, ensuring a robust supply of high-quality APIs in the market.

Intas Pharmaceuticals stands as a significant contender in the India Montelukast API Market, exemplifying strength through its extensive product portfolio and commitment to research and development. The firm has established its presence through its high-quality production capabilities while maintaining compliance with national and international regulatory standards.

Intas has dedicated substantial resources to R&D, facilitating the introduction of various formulations and generics that cater to the growing needs of patients with respiratory conditions. With robust distribution networks across India, Intas Pharmaceuticals ensures that its Montelukast products are readily available to consumers, thereby strengthening its market influence.

The company's strategic focus on quality and affordable pricing has allowed it to capture a considerable share of the Indian Montelukast segment, highlighting its role as a leader in this competitive landscape.

Jubilant Life Sciences has carved out a noteworthy position within the India Montelukast API Market through its strong focus on manufacturing and supply chain efficiency. Known for its commitment to producing high-quality APIs, the company has integrated advanced technologies into its production processes, ensuring scalability and consistency in its offerings.

Jubilant's portfolio includes a range of products designed to meet various needs in the respiratory therapeutic area, demonstrating its expertise in Montelukast formulations. The company has established a solid market presence due to its strategic partnerships and collaborations, which have bolstered its capabilities and expanded its reach within India.

Furthermore, Jubilant Life Sciences has engaged in mergers and acquisitions that have enhanced its operational strength and boosted its innovation capacity, allowing it to navigate competitive challenges effectively. By continually investing in R&D and maintaining high-quality standards, Jubilant remains a vital player in the Montelukast API segment, contributing to advancements in respiratory healthcare in India.

### **Key Companies in the India Montelukast API Market Include**

### **India Montelukast API Market Industry Developments**

The India Montelukast API Market has witnessed significant developments recently, particularly with the rising demand driven by the increase in respiratory diseases. Companies such as Dr. Reddy's Laboratories and Cipla have reported growth in market valuation due to their successful product launches and improved production capabilities.

In September 2023, Intas Pharmaceuticals expanded its manufacturing facility to enhance its Montelukast API production capacity, contributing to the competitive landscape. Additionally, in August 2023, Jubilant Life Sciences announced an agreement with Zydus Cadila to collaborate on expanding Montelukast API production, indicating a shift towards strategic partnerships.

Major players like Torrent Pharmaceuticals and Glenmark Pharmaceuticals are also focusing on Research and Development to innovate and streamline their Montelukast offerings. Furthermore, mergers and acquisitions have shaped market dynamics, with Aurobindo Pharma acquiring a portfolio of products related to Montelukast API in March 2022, emphasizing the trend of consolidating capabilities among key manufacturers.

Overall, these developments underscore a vibrant and evolving Montelukast API sector in India, characterized by strategic initiatives and robust market growth prospects.

### **Montelukast API Market Segmentation Insights**

### **Montelukast API Market Application Outlook**

## Market Drivers

### Competitive Landscape and Market Dynamics

The montelukast api market is characterized by a competitive landscape with numerous players vying for market share. The presence of both multinational corporations and local manufacturers is intensifying competition, leading to price reductions and improved product offerings. This dynamic environment is likely to benefit consumers through increased availability and affordability of montelukast. Furthermore, strategic partnerships and collaborations among companies are expected to enhance research capabilities and expand distribution networks. As the market evolves, companies are likely to focus on differentiating their products through quality and innovation, which could further stimulate growth in the montelukast api market.

### Rising Awareness of Preventive Healthcare

There is a growing trend towards preventive healthcare in India, which is influencing the montelukast api market. Patients and healthcare providers are increasingly recognizing the importance of managing respiratory conditions proactively. This shift in mindset is likely to lead to higher prescriptions of montelukast as a preventive measure against asthma attacks and allergic reactions. The market is projected to grow as more individuals seek to manage their health conditions before they escalate. Furthermore, educational campaigns by healthcare organizations are enhancing awareness about the benefits of montelukast, which may contribute to its increased adoption in treatment regimens. Consequently, the montelukast api market could see a notable rise in demand as preventive healthcare becomes a priority.

### Increasing Prevalence of Allergic Conditions

The montelukast api market in India is experiencing growth due to the rising prevalence of allergic conditions such as asthma and allergic rhinitis. According to recent health surveys, approximately 10-15% of the Indian population suffers from asthma, which is a significant driver for the demand for montelukast. This increase in respiratory disorders necessitates effective treatment options, thereby boosting the montelukast api market. Furthermore, the growing awareness among healthcare professionals and patients regarding the benefits of montelukast in managing these conditions is likely to enhance market penetration. As a result, pharmaceutical companies are focusing on expanding their montelukast production capabilities to meet the increasing demand, which could lead to a more competitive landscape in the montelukast api market.

### Technological Advancements in Drug Formulation

Innovations in drug formulation technology are playing a crucial role in shaping the montelukast api market. The development of advanced delivery systems, such as inhalers and oral tablets, is enhancing the efficacy and patient compliance of montelukast. These technological advancements are likely to attract more patients towards using montelukast for managing their respiratory conditions. Additionally, the integration of digital health solutions, such as mobile applications for medication management, is expected to further boost the market. As pharmaceutical companies invest in research and development to improve montelukast formulations, the montelukast api market may experience significant growth driven by these innovations.

### Government Initiatives for Healthcare Improvement

The Indian government has been actively promoting healthcare initiatives aimed at improving access to essential medicines, including those for respiratory conditions. Programs aimed at enhancing healthcare infrastructure and affordability are likely to positively impact the montelukast api market. The government's focus on increasing the availability of generic medications has led to a surge in the production of montelukast, making it more accessible to patients. Additionally, the implementation of the National Health Mission has further emphasized the importance of treating chronic respiratory diseases, which could drive the demand for montelukast. As a result, the montelukast api market is expected to benefit from these initiatives, potentially leading to increased sales and market growth.

## Future Outlook

The [Montelukast API Market](https://www.marketresearchfuture.com/reports/montelukast-api-market-7886) is projected to grow at a 10.8% CAGR from 2025 to 2035, driven by increasing asthma prevalence, rising healthcare expenditure, and advancements in drug formulation.

**New opportunities:**

- Expansion of online distribution channels for montelukast APIs
- Development of combination therapies to enhance efficacy
- Investment in R&D for novel delivery systems to improve patient compliance

By 2035, the montelukast API market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Asthma (Largest) vs. Allergic Rhinitis (Fastest-Growing)

In the India montelukast api market, the application segment is prominently led by asthma, which captures the largest market share due to the high prevalence of the condition in the region. Allergic rhinitis follows, with substantial numbers as well, though it represents a smaller portion of the market. Other applications such as bronchospasm, urticaria, and others are gaining traction but do not hold significant shares compared to asthma and allergic rhinitis.

Looking ahead, the growth trends in this segment are being driven by increasing respiratory ailments, heightened environmental pollution, and greater awareness of treatments available. Additionally, the rise in allergic disorders is also contributing to the demand for montelukast therapies, with health professionals increasingly prescribing them to address various conditions such as allergic rhinitis and bronchospasms. The market is set for growth as these health issues become more prevalent in the population.

Asthma (Dominant) vs. Allergic Rhinitis (Emerging)

Asthma stands out as the dominant application within the India montelukast api market, characterized by its high incidence rates and the critical need for effective management solutions. Patients suffering from asthma rely heavily on montelukast to control inflammation and bronchoconstriction. On the other hand, allergic rhinitis is emerging as a significant application area, driven by increasing awareness and diagnosis of allergic conditions. While asthma maintains a strong position, allergic rhinitis is rapidly gaining acceptance among healthcare providers and patients alike, reflecting a growing understanding of the condition and its management through montelukast. As healthcare systems evolve, both segments will continue to play vital roles in shaping the future landscape of respiratory treatments.

## Competitive Benchmarking

The montelukast API market in India is characterized by a competitive landscape that is both dynamic and multifaceted. Key growth drivers include the increasing prevalence of asthma and allergic rhinitis, alongside a rising demand for cost-effective therapeutic options. Major players such as Merck & Co (US), Cipla Ltd (IN), and Aurobindo Pharma Ltd (IN) are strategically positioned to leverage their extensive manufacturing capabilities and established distribution networks. These companies appear to focus on innovation and regional expansion, which collectively shapes a competitive environment that is increasingly reliant on technological advancements and strategic partnerships.In terms of business tactics, localizing manufacturing and optimizing supply chains are pivotal strategies employed by these companies. The market structure is moderately fragmented, with several players vying for market share. This fragmentation allows for a diverse range of products and pricing strategies, although the influence of key players remains substantial, often dictating market trends and consumer preferences.

In October  Merck & Co (US) announced a collaboration with a leading Indian biotech firm to enhance the production of montelukast API, aiming to streamline supply chains and reduce costs. This strategic move is likely to bolster Merck's market position by ensuring a more reliable supply of its products while also tapping into local expertise and resources. Such collaborations may enhance operational efficiencies and foster innovation in product development.

In September  Cipla Ltd (IN) launched a new montelukast formulation aimed at pediatric patients, reflecting its commitment to addressing specific market needs. This initiative not only diversifies Cipla's product portfolio but also positions the company as a leader in specialized therapeutic solutions. The focus on pediatric formulations could potentially capture a significant share of the market, given the increasing awareness of asthma management in children.

In August  Aurobindo Pharma Ltd (IN) expanded its manufacturing capabilities by investing in a new facility dedicated to the production of montelukast API. This expansion is indicative of Aurobindo's strategy to enhance its production capacity and meet the growing demand in both domestic and international markets. Such investments are crucial for maintaining competitive advantage and ensuring supply chain reliability in a rapidly evolving market.

As of November  current competitive trends are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing operational efficiencies. The shift from price-based competition to a focus on technological advancements and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and adapt to changing market dynamics.

## Recent News & Developments

The India Montelukast API Market has witnessed significant developments recently, particularly with the rising demand driven by the increase in respiratory diseases. Companies such as Dr. Reddy's Laboratories and Cipla have reported growth in market valuation due to their successful product launches and improved production capabilities.

In September 2023, Intas Pharmaceuticals expanded its manufacturing facility to enhance its Montelukast API production capacity, contributing to the competitive landscape. Additionally, in August 2023, Jubilant Life Sciences announced an agreement with Zydus Cadila to collaborate on expanding Montelukast API production, indicating a shift towards strategic partnerships.

Major players like Torrent Pharmaceuticals and Glenmark Pharmaceuticals are also focusing on Research and Development to innovate and streamline their Montelukast offerings. Furthermore, mergers and acquisitions have shaped market dynamics, with Aurobindo Pharma acquiring a portfolio of products related to Montelukast API in March 2022, emphasizing the trend of consolidating capabilities among key manufacturers.

Overall, these developments underscore a vibrant and evolving Montelukast API sector in India, characterized by strategic initiatives and robust market growth prospects.

## Report Scope

| MARKET SIZE 2024 | 50.5(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 55.95(USD Million) |
| MARKET SIZE 2035 | 156.07(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.8% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Merck & Co (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Cipla Ltd (IN), Aurobindo Pharma Ltd (IN), Hikma Pharmaceuticals PLC (GB), Zydus Cadila (IN), Sun Pharmaceutical Industries Ltd (IN) |
| Segments Covered | Application |
| Key Market Opportunities | Growing demand for montelukast API driven by rising respiratory disorders and regulatory support for generic formulations. |
| Key Market Dynamics | Regulatory changes and competitive pressures drive innovation in the montelukast active pharmaceutical ingredient market. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What was the market valuation of the India montelukast API market in 2024?**
A: The market valuation was $50.5 Million in 2024.

**Q: What is the projected market valuation for the India montelukast API market by 2035?**
A: The projected valuation for 2035 is $156.07 Million.

**Q: What is the expected CAGR for the India montelukast API market during the forecast period 2025 - 2035?**
A: The expected CAGR is 10.8% during the forecast period 2025 - 2035.

**Q: Which companies are the key players in the India montelukast API market?**
A: Key players include Merck & Co, Mylan N.V., Teva Pharmaceutical Industries Ltd, Cipla Ltd, Aurobindo Pharma Ltd, Hikma Pharmaceuticals PLC, Zydus Cadila, and Sun Pharmaceutical Industries Ltd.

**Q: What are the main application segments for montelukast API in India?**
A: The main application segments include Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, and Others.

**Q: What was the market size for the Asthma segment in 2024?**
A: The market size for the Asthma segment was $15.0 Million to $45.0 Million in 2024.

**Q: What is the projected market size for the Allergic Rhinitis segment by 2035?**
A: The projected market size for the Allergic Rhinitis segment is $10.0 Million to $30.0 Million by 2035.

**Q: How does the market size for Bronchospasm compare to Urticaria in 2024?**
A: In 2024, the market size for Bronchospasm ranged from $8.0 Million to $25.0 Million, whereas Urticaria ranged from $5.0 Million to $20.0 Million.

**Q: What is the potential growth for the Others segment in the montelukast API market?**
A: The Others segment had a market size of $12.5 Million to $36.07 Million in 2024, indicating potential growth.

**Q: How do the key players influence the montelukast API market in India?**
A: Key players like Merck & Co and Cipla Ltd likely influence the market through innovation and competitive pricing.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-montelukast-api-market-53097*